The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab
Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various im...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2017/06/01, Vol.56(11), pp.1435-1438 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1438 |
|---|---|
| container_issue | 11 |
| container_start_page | 1435 |
| container_title | Internal Medicine |
| container_volume | 56 |
| creator | Matsuo, Satoko Hayashi, Keigo Morimoto, Eisaku Kato, Ayako Sada, Ken-Ei Watanabe, Haruki Takano-Narazaki, Mariko Sunahori-Watanabe, Katsue Kawabata, Tomoko Wada, Jun |
| description | Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments. |
| doi_str_mv | 10.2169/internalmedicine.56.8235 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5498213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2014494738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c667t-2b44163759d7123f9f085a6293e7ab8cd102eaffdea94b7726b40fb013512b9d3</originalsourceid><addsrcrecordid>eNptkU9rGzEQxUVpady0X6Es9NLLuvq30upSKCFNAiYpiXMWWu3IlllLqbRb6m9fGbumDbmMBPrNm6d5CFUEzykR6osPI6Rghi303voA80bMW8qaV2hGGFe1LPfXaIYVaWtayhl6l_MGY9ZKRd-iM9o2QghCZ2ixXEP1MFkLObtpqJYJzLiFMFbRVffgkrFjTLvqRxx2JpWpfvS5uo19zKZ6zD6sqpvgBv_bb033Hr1xZsjw4Xieo8fvl8uL63pxd3Vz8W1RWyHkWNOOcyKYbFQvCWVOOdw2RlDFQJqutT3BFIxzPRjFOymp6Dh2HSasIbRTPTtHXw-6T1NXVmCL3WQG_ZSKibTT0Xj9_0vwa72Kv3TDVUsJKwKfjwIp_pwgj3rrs4VhMAHilDVRmCtMpJIF_fQM3cRpv_usKSacKy5ZW6j2QNkUc07gTmYI1vvI9PPIdCP0PrLS-vHfz5wa_2ZUgLsDsMmjWcEJKHF4O8CLyoTs63HEibRrkzQE9ge-TrYj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014494738</pqid></control><display><type>article</type><title>The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Matsuo, Satoko ; Hayashi, Keigo ; Morimoto, Eisaku ; Kato, Ayako ; Sada, Ken-Ei ; Watanabe, Haruki ; Takano-Narazaki, Mariko ; Sunahori-Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun</creator><creatorcontrib>Matsuo, Satoko ; Hayashi, Keigo ; Morimoto, Eisaku ; Kato, Ayako ; Sada, Ken-Ei ; Watanabe, Haruki ; Takano-Narazaki, Mariko ; Sunahori-Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun</creatorcontrib><description>Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.56.8235</identifier><identifier>PMID: 28566612</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Arteritis ; Blood vessels ; Case Report ; Cyclophosphamide ; Cyclophosphamide - therapeutic use ; Glucocorticoids ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive agents ; Immunosuppressive Agents - therapeutic use ; Infliximab ; Infliximab - therapeutic use ; Internal medicine ; Male ; Methotrexate ; Methotrexate - therapeutic use ; Middle Aged ; Monoclonal antibodies ; polyarteritis nodosa ; Polyarteritis Nodosa - diagnosis ; Polyarteritis Nodosa - drug therapy ; Remission ; Rituximab ; Treatment Outcome ; Tumor necrosis factor-α</subject><ispartof>Internal Medicine, 2017/06/01, Vol.56(11), pp.1435-1438</ispartof><rights>2017 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><rights>Copyright © 2017 by The Japanese Society of Internal Medicine 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c667t-2b44163759d7123f9f085a6293e7ab8cd102eaffdea94b7726b40fb013512b9d3</citedby><cites>FETCH-LOGICAL-c667t-2b44163759d7123f9f085a6293e7ab8cd102eaffdea94b7726b40fb013512b9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498213/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498213/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28566612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuo, Satoko</creatorcontrib><creatorcontrib>Hayashi, Keigo</creatorcontrib><creatorcontrib>Morimoto, Eisaku</creatorcontrib><creatorcontrib>Kato, Ayako</creatorcontrib><creatorcontrib>Sada, Ken-Ei</creatorcontrib><creatorcontrib>Watanabe, Haruki</creatorcontrib><creatorcontrib>Takano-Narazaki, Mariko</creatorcontrib><creatorcontrib>Sunahori-Watanabe, Katsue</creatorcontrib><creatorcontrib>Kawabata, Tomoko</creatorcontrib><creatorcontrib>Wada, Jun</creatorcontrib><title>The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.</description><subject>Arteritis</subject><subject>Blood vessels</subject><subject>Case Report</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infliximab</subject><subject>Infliximab - therapeutic use</subject><subject>Internal medicine</subject><subject>Male</subject><subject>Methotrexate</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>polyarteritis nodosa</subject><subject>Polyarteritis Nodosa - diagnosis</subject><subject>Polyarteritis Nodosa - drug therapy</subject><subject>Remission</subject><subject>Rituximab</subject><subject>Treatment Outcome</subject><subject>Tumor necrosis factor-α</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU9rGzEQxUVpady0X6Es9NLLuvq30upSKCFNAiYpiXMWWu3IlllLqbRb6m9fGbumDbmMBPrNm6d5CFUEzykR6osPI6Rghi303voA80bMW8qaV2hGGFe1LPfXaIYVaWtayhl6l_MGY9ZKRd-iM9o2QghCZ2ixXEP1MFkLObtpqJYJzLiFMFbRVffgkrFjTLvqRxx2JpWpfvS5uo19zKZ6zD6sqpvgBv_bb033Hr1xZsjw4Xieo8fvl8uL63pxd3Vz8W1RWyHkWNOOcyKYbFQvCWVOOdw2RlDFQJqutT3BFIxzPRjFOymp6Dh2HSasIbRTPTtHXw-6T1NXVmCL3WQG_ZSKibTT0Xj9_0vwa72Kv3TDVUsJKwKfjwIp_pwgj3rrs4VhMAHilDVRmCtMpJIF_fQM3cRpv_usKSacKy5ZW6j2QNkUc07gTmYI1vvI9PPIdCP0PrLS-vHfz5wa_2ZUgLsDsMmjWcEJKHF4O8CLyoTs63HEibRrkzQE9ge-TrYj</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Matsuo, Satoko</creator><creator>Hayashi, Keigo</creator><creator>Morimoto, Eisaku</creator><creator>Kato, Ayako</creator><creator>Sada, Ken-Ei</creator><creator>Watanabe, Haruki</creator><creator>Takano-Narazaki, Mariko</creator><creator>Sunahori-Watanabe, Katsue</creator><creator>Kawabata, Tomoko</creator><creator>Wada, Jun</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab</title><author>Matsuo, Satoko ; Hayashi, Keigo ; Morimoto, Eisaku ; Kato, Ayako ; Sada, Ken-Ei ; Watanabe, Haruki ; Takano-Narazaki, Mariko ; Sunahori-Watanabe, Katsue ; Kawabata, Tomoko ; Wada, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c667t-2b44163759d7123f9f085a6293e7ab8cd102eaffdea94b7726b40fb013512b9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Arteritis</topic><topic>Blood vessels</topic><topic>Case Report</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infliximab</topic><topic>Infliximab - therapeutic use</topic><topic>Internal medicine</topic><topic>Male</topic><topic>Methotrexate</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>polyarteritis nodosa</topic><topic>Polyarteritis Nodosa - diagnosis</topic><topic>Polyarteritis Nodosa - drug therapy</topic><topic>Remission</topic><topic>Rituximab</topic><topic>Treatment Outcome</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsuo, Satoko</creatorcontrib><creatorcontrib>Hayashi, Keigo</creatorcontrib><creatorcontrib>Morimoto, Eisaku</creatorcontrib><creatorcontrib>Kato, Ayako</creatorcontrib><creatorcontrib>Sada, Ken-Ei</creatorcontrib><creatorcontrib>Watanabe, Haruki</creatorcontrib><creatorcontrib>Takano-Narazaki, Mariko</creatorcontrib><creatorcontrib>Sunahori-Watanabe, Katsue</creatorcontrib><creatorcontrib>Kawabata, Tomoko</creatorcontrib><creatorcontrib>Wada, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuo, Satoko</au><au>Hayashi, Keigo</au><au>Morimoto, Eisaku</au><au>Kato, Ayako</au><au>Sada, Ken-Ei</au><au>Watanabe, Haruki</au><au>Takano-Narazaki, Mariko</au><au>Sunahori-Watanabe, Katsue</au><au>Kawabata, Tomoko</au><au>Wada, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>56</volume><issue>11</issue><spage>1435</spage><epage>1438</epage><pages>1435-1438</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>28566612</pmid><doi>10.2169/internalmedicine.56.8235</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2017/06/01, Vol.56(11), pp.1435-1438 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5498213 |
| source | J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access |
| subjects | Arteritis Blood vessels Case Report Cyclophosphamide Cyclophosphamide - therapeutic use Glucocorticoids Glucocorticoids - therapeutic use Humans Immunosuppressive agents Immunosuppressive Agents - therapeutic use Infliximab Infliximab - therapeutic use Internal medicine Male Methotrexate Methotrexate - therapeutic use Middle Aged Monoclonal antibodies polyarteritis nodosa Polyarteritis Nodosa - diagnosis Polyarteritis Nodosa - drug therapy Remission Rituximab Treatment Outcome Tumor necrosis factor-α |
| title | The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A47%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Successful%20Treatment%20of%20Refractory%20Polyarteritis%20Nodosa%20Using%20Infliximab&rft.jtitle=Internal%20Medicine&rft.au=Matsuo,%20Satoko&rft.date=2017-01-01&rft.volume=56&rft.issue=11&rft.spage=1435&rft.epage=1438&rft.pages=1435-1438&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.56.8235&rft_dat=%3Cproquest_pubme%3E2014494738%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014494738&rft_id=info:pmid/28566612&rfr_iscdi=true |